|
|
 |
 |
| News Release |
|
 |

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. |
| 2002 Release |
 |
| December 20, 2002 |  |
Notice Concerning Subsidiary Dissolution
|  |
| December 11, 2002 |  |
Eisai Launches SKAINAR COOL FOR RHINITIS and SKAINAR SPRAY FOR RHINITIS for Allergic and Acute Rhinitis
|  |
| November 14, 2002 |  |
ACIPHEX , Proton Pump Inhibitor, First Seven-Day Treatment of H.pylori Infection Approved by FDA
|  |
| November 13, 2002 |  |
Eisai transfers Veterinary and Livestock Feed Products Business to Meiji Seika
|  |
| November 5, 2002 |  |
Eisai Submits Vascular Dementia Marketing Authorization Application for ARICEPT in the U.K.
|  |
| October 24, 2002 |  |
Neurogenetics, Inc. Extends Agreement With Eisai Co., Ltd.
|  |
| October 17, 2002 |  |
Eisai Launches DENTAKE DENTAL RINSE and DENTAKE MEDICATED TOOTH PASTE for Prevention against Periodontal Diseases
|  |
| October 10, 2002 |  |
Environmental Study Results of Eisai Site in Funado, Itabashi-ku
|  |
| October 4, 2002 |  |
Eisai Launches SACLON FRESH Drink Refreshing Relief from Upset Stomach
|  |
| October 4, 2002 |  |
Eisai Launches BREATHE RIGHT KIDS TYPE Nasal Strips for Children of Age 5-12
|  |
| September 4, 2002 |  |
Eisai Submits sNDA for ARICEPT for Treatment of Vascular Dementia (VaD)
|  |
| August 20, 2002 |  |
Notice Concerning Acquisition of the Company's Own Shares in the Market
|  |
| August 20, 2002 |  |
Eisai Launches JUVELUX L For Relief of Hot and Cold Flashes Associated with Menopause
|  |
| July 25, 2002 |  |
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., to Promote a Pfizer Product
|  |
| July 2, 2002 |  |
Eisai Launches TRAVELMIN FAMILY - A Motion Sickness Medication That Dissolves Quickly In The Mouth -
|  |
| July 1, 2002 |  |
Notice Concerning Stock Options Including the Amount to Be Paid for the Exercise of Stock Options
|  |
| June 27, 2002 |  |
Notice of Allotment of Stock Options
|  |
| May 14, 2002 |  |
Notice Concerning Acquisition of the Company's Own Shares in the Market
|  |
| May 14, 2002 |  |
Notice on Providing Stock Options in the Form of New Stock Issuance
|  |
| May 14, 2002 |  |
Eisai Establishes Clinical Research Subsidiary in the United States
|  |
| April 17, 2002 |  |
Vascular Dementia Phase III Clinical Trial Results for ARICEPT , an ALZHEIMER'S Disease Treatment, Announced at an Academic Conference
|  |
| March 26, 2002 |  |
Eisai Announces the Merger of Six Japan-based Subsidiaries
|  |
| March 20, 2002 |  |
Aventis Pharma Ltd. and Eisai Co., Ltd. Announce Copromotion Agreement for the Osteoporosis Therapeutic Agent, ACTONEL 2.5 mg
|  |
| February 25, 2002 |  |
Notice of Acquisition Completion of the Company's Own Shares through ToSTNeT-2
|  |
| February 22, 2002 |  |
Notice Concerning Acquisition of the Company's Own Shares in the Market
|  |
| February 22, 2002 |  |
Notice of Acquisition of the Company's Own Shares through ToSTNeT-2
|  |
| February 22, 2002 |  |
Notice of Revision of Forecast Year End Dividend For Fiscal Year Period (90th Company Fiscal Period) Ending March 2002
|  |
| February 21, 2002 |  |
Eisai S.A. in France Acquires All Shares of BIODIM S.A.S.
|  |
| February 15, 2002 |  |
ACIPHEX Receives Approval for the Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) in the U.S.
|  |
| January 25, 2002 |  |
Vascular Dementia Phase III Clinical Trial Results for Aricept , an Alzheimer's Disease Treatment, Announced at an Academic Conference
|  |
| January 16, 2002 |  |
Eisai Files Application for a New Indication for ACIPHEX in the U.S. For H. Pylori Eradication
|  |
| January 7, 2002 |  |
Eisai Files Application for Indication Expansion in Japan for PARIET  |  |
 |  |  |  |
|
|
 |